Adobe Gastroenterology, PC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$358,862	1
2024	Research	$760,450	2
2023	Research	$360,837	2
2021	Research	$3,988	6
2020	Research	$13,917	14
2019	Research	$897	16

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $1,480,149 5 payments
Novo Nordisk AS $18,802 36 payments

Studies the money was for Research payments · program years 2019–2025

A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $930,579 2 payments
COSMOS - A Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Safety Tolerability and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis $535,870 2 payments
Nn9931-4296 $18,802 36 payments
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis $13,700 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.